BioWorld Asia

April 14, 2004

Adprotech Being Acquired By Inflazyme In C$20M Deal

LONDON - Last week, shareholders in privately held Adprotech Ltd. agreed to be taken over by Inflazyme Pharmaceuticals Ltd. for about C$20 million (US$14.9 million) in shares. (BioWorld International) Read More

EuropaBio Probes Fairness To Biotech In New EU Rules

Interfering RNA Libraries Might Boost Mammalian Gene Insight

Start-up Opsona Focused On Toll-Like Receptor Signaling

Although Cleared For Planting, Bayer Ditching UK Maize Plans

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 13, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

BioWorld

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...